Literature DB >> 18347112

Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.

Susanne Perkhofer1, Daniel Jost, Manfred P Dierich, Cornelia Lass-Flörl.   

Abstract

MICs and fractional inhibitory concentrations were evaluated for anidulafungin and voriconazole alone and in combination against conidia and hyphae under hypoxic (1% oxygen-5% CO(2)-94% nitrogen) conditions against 31 Aspergillus isolates. Anidulafungin exhibited excellent activity against conidia and hyphae of Aspergillus spp. The visual reading of the MIC for anidulafungin was optimal under hypoxic conditions.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18347112      PMCID： PMC2346651          DOI： 10.1128/AAC.01572-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  The past, present and future of antimycotic combination therapy.

Authors:  A Polak
Journal:  Mycoses       Date:  1999       Impact factor: 4.377

2.  Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida.

Authors:  Peter A Warn; A Sharp; J Guinea; David W Denning
Journal:  J Antimicrob Chemother       Date:  2004-03-24       Impact factor: 5.790

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 4.  Anidulafungin: a novel echinocandin.

Authors:  Jose A Vazquez; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2006-06-09       Impact factor: 9.079

5.  In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

6.  Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.

Authors:  William R Kirkpatrick; Sofia Perea; Brent J Coco; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds.

Authors:  A Espinel-Ingroff; A Fothergill; M Ghannoum; E Manavathu; L Ostrosky-Zeichner; M A Pfaller; M G Rinaldi; W Schell; T J Walsh
Journal:  J Clin Microbiol       Date:  2007-05-02       Impact factor: 5.948

8.  In vitro studies on the activity of amphotericin B and lipid-based amphotericin B formulations against Aspergillus conidia and hyphae.

Authors:  Cornelia Lass-Flörl; M Nagl; E Gunsilius; C Speth; H Ulmer; R Würzner
Journal:  Mycoses       Date:  2002-06       Impact factor: 4.377

9.  Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus.

Authors:  J Dotis; M Simitsopoulou; M Dalakiouridou; T Konstantinou; A Taparkou; F Kanakoudi-Tsakalidou; T J Walsh; E Roilides
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

Authors:  Sofia Perea; Gloria Gonzalez; Annette W Fothergill; William R Kirkpatrick; Michael G Rinaldi; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191
View more
  14 in total

1.  In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp.

Authors:  Virginie Planche; Sebastien Ducroz; Alexandre Alanio; Marie-Elisabeth Bougnoux; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

2.  In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Authors:  Susanne Perkhofer; Cornelia Mrazek; Lukas Hartl; Cornelia Lass-Flörl
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

3.  Susceptibility profiles of amphotericin B and posaconazole against clinically relevant mucorales species under hypoxic conditions.

Authors:  Elisabeth Maurer; Ulrike Binder; Manuela Sparber; Michaela Lackner; Rita Caramalho; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

Review 4.  Hypoxia and fungal pathogenesis: to air or not to air?

Authors:  Nora Grahl; Kelly M Shepardson; Dawoon Chung; Robert A Cramer
Journal:  Eukaryot Cell       Date:  2012-03-23

5.  Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus.

Authors:  Enrique Calvo; F Javier Pastor; Valentina Salas; Emilio Mayayo; Josep Guarro
Journal:  Mycopathologia       Date:  2011-12-04       Impact factor: 2.574

Review 6.  Implications of hypoxic microenvironments during invasive aspergillosis.

Authors:  Sara J Wezensky; Robert A Cramer
Journal:  Med Mycol       Date:  2010-06-21       Impact factor: 4.076

7.  Effect of reduced oxygen on the antifungal susceptibility of clinically relevant aspergilli.

Authors:  Ulrike Binder; Elisabeth Maurer; Michaela Lackner; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2014-12-29       Impact factor: 5.191

Review 8.  Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.

Authors:  Effie L Kuti; Joseph L Kuti
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10       Impact factor: 4.481

9.  Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.

Authors:  Wendy W J van de Sande; Ron A A Mathot; Marian T ten Kate; Wim van Vianen; Mehri Tavakol; Bart J A Rijnders; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

10.  Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Authors:  Jared L Crandon; Mary Anne Banevicius; Annie F Fang; Penelope H Crownover; R Fredrick Knauft; J Samuel Pope; John H Russomanno; Eric Shore; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.